Safety of adding salmeterol to fluticasone propionate in children with asthma

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 840-849

  Stempel, David A ^a   Szefler, Stanley J ^d   Pedersen, SØren ^e   Zeiger, Robert S ^f   Yeakey, Anne M ^a   Lee, Laurie A ^a   Liu, Andrew H ^d   Mitchell, Herman ^b   Kral, Kenneth M ^a   Raphiou, Ibrahim H ^a   Prillaman, Barbara A ^c   Buaron, Kathleen S ^a   Kirby, Suyong Yun ^a   Pascoe, Steven J ^a  

^a GLAXOSMITHKLINE   (United States)

^b Rho   (United States)

^c PAREXEL INTERNATIONAL   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

^e KOLDING HOSPITAL   (Denmark)

^f KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DELAYED RELEASE FORMULATION; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE;

ARTICLE; ASTHMA; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; ENDOTRACHEAL INTUBATION; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METERED DOSE INHALER; MULTICENTER STUDY; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; STATISTICAL ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; INHALATIONAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-1 RECEPTOR AGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; HUMANS; MALE; METERED DOSE INHALERS; PROPORTIONAL HAZARDS MODELS;

EID: 84985930891     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1606356     Document Type: Article

References (25)

1. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1968; 1: 335-9.
2. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: Case-control study. Lancet 1989; 1: 917-22.
3. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-6.
4. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled betaagonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993; 148: 75-9.
5. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604-10.
6. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-7.
7. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26.
8. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Silver Spring, MD: Food and Drug Administration, November 2008 (http://www .fda .gov/ ohrms/ dockets/ ac/ 08/ briefing/ 2008 -4398b1-01-FDA .pdf).
9. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65: 39-43.
10. Stempel DA, Raphiou IH, Kral KM, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med 2016; 374: 1822-30.
11. Drazen JM, O'Byrne PM. Risks of longacting beta-agonists in achieving asthma control. N Engl J Med 2009; 360: 1671-2.
12. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2- adrenergic receptor agonists. Pediatrics 2011; 128(5): E1147-54.
13. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007; 119: 817-25.
14. Voorend-van Bergen S, Vaessen-Verberne AA, Landstra AM, et al. Monitoring childhood asthma: web-based diaries and the asthma control test. J Allergy Clin Immunol 2014; 133(6): 1599-605.e2.
15. Prescribing information for Advair Diskus. Research Triangle Park, NC: GlaxoSmithKline, April 2014 (https:/ / www .gsksource .com/ pharma/ content/ dam/ GlaxoSmithKline/ US/ en/ Prescribing- Information/ Advair-Diskus/ pdf/ ADVAIR -DISKUS-PI-MG .PDF).
16. Cytel East 5 user manual. Cambridge, MA: Cytel 2007.
17. Jennison CTB. Group sequential methods with applications to clinical trials. London: Chapman and Hall/CRC, 2000.
18. Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2009-2010. Vital Health Stat 3 2012; 1-58.
19. Guidelines for the diagnosis and management of asthma (EPR-3). Bethesda, MD: National Institutes of Health, July 2007 (http://www .nhlbi .nih .gov/ health-pro/ guidelines/ current/ asthma-guidelines/ ).
20. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2016 (http://ginasthma .org/ 2016-gina-report-global-strategy-for -asthma-management-and-prevention/ ).
21. Russell G, Williams DA, Weller P, Price JF. Salmeterol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995; 75: 423-8.
22. Zimmerman B, D'Urzo A, Berube D. Efficacy and safety of formoterol Turbuhaler when added to inhaled corticosteroid treatment in children with asthma. Pediatr Pulmonol 2004; 37: 122-7.
23. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010; 182: 1221-7.
24. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975-85.
25. Bauman LJ, Wright E, Leickly FE, et al. Relationship of adherence to pediatric asthma morbidity among inner-city children. Pediatrics 2002; 110(1): E6.